University of Vermont Vaccine Testing Center
Welcome,         Profile    Billing    Logout  
 9 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wright, Peter
NCT04529538: Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines

Completed
1
226
US
Novel Oral Polio Vaccine Type 1 (nOPV1), Novel Oral Polio Vaccine Type 3 (nOPV3), Sabin Monovalent Oral Polio Vaccine Type 1 (mOPV1), Sabin Monovalent Oral Polio Vaccine Type 3 (mOPV3), Sabin monovalent oral polio vaccine type 3
PATH, Bill and Melinda Gates Foundation, Centers for Disease Control and Prevention, Viroclinics Biosciences B.V., The Emmes Company, LLC
Poliomyelitis
02/23
02/23
Kirkpatrick, Beth
NCT05229354: Dengue Controlled Human Infection Model in Dhaka, Bangladesh

Active, not recruiting
2
192
RoW
TV005, rDEN2Δ30-7169 attenuated virus strain, rDEN2Δ30-7169 Lot DEN2#121A
Beth Kirkpatrick, International Centre for Diarrhoeal Disease Research, Bangladesh
Dengue
11/23
07/25
Al-Ibrahim, Mohamed S
NCT05933525: Clinical Study to Assess the Efficacy of IMM-124E (Travelan®) in a Controlled Human Infection Model

Active, not recruiting
2
60
US
Travelan, IMM-124E, Placebo, ProMilk 85 milk powder
Immuron Ltd., United States Department of Defense, Naval Medical Research Center
Diarrhea, Travelers Diarrhea, Infectious Diarrhea
04/24
07/24
NCT04768452: A SAD/MAD Study to Evaluate the Safety, Tolerability, PK and PD of MT2004

Recruiting
1
80
US
MT2004, Placebo
Shaanxi Micot Technology Limited Company
Healthy
05/21
08/21
NCT04529538: Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines

Completed
1
226
US
Novel Oral Polio Vaccine Type 1 (nOPV1), Novel Oral Polio Vaccine Type 3 (nOPV3), Sabin Monovalent Oral Polio Vaccine Type 1 (mOPV1), Sabin Monovalent Oral Polio Vaccine Type 3 (mOPV3), Sabin monovalent oral polio vaccine type 3
PATH, Bill and Melinda Gates Foundation, Centers for Disease Control and Prevention, Viroclinics Biosciences B.V., The Emmes Company, LLC
Poliomyelitis
02/23
02/23
Sena, Arlene
NCT04529538: Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines

Completed
1
226
US
Novel Oral Polio Vaccine Type 1 (nOPV1), Novel Oral Polio Vaccine Type 3 (nOPV3), Sabin Monovalent Oral Polio Vaccine Type 1 (mOPV1), Sabin Monovalent Oral Polio Vaccine Type 3 (mOPV3), Sabin monovalent oral polio vaccine type 3
PATH, Bill and Melinda Gates Foundation, Centers for Disease Control and Prevention, Viroclinics Biosciences B.V., The Emmes Company, LLC
Poliomyelitis
02/23
02/23
Crothers, Jessica
NCT04529538: Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines

Completed
1
226
US
Novel Oral Polio Vaccine Type 1 (nOPV1), Novel Oral Polio Vaccine Type 3 (nOPV3), Sabin Monovalent Oral Polio Vaccine Type 1 (mOPV1), Sabin Monovalent Oral Polio Vaccine Type 3 (mOPV3), Sabin monovalent oral polio vaccine type 3
PATH, Bill and Melinda Gates Foundation, Centers for Disease Control and Prevention, Viroclinics Biosciences B.V., The Emmes Company, LLC
Poliomyelitis
02/23
02/23
NCT05327426: Intradermal Fractional Dose IPV (fIPV) in Combination With dmLT

Active, not recruiting
1
19
US
Intradermal fractional dose inactivated polio vaccine (fIPV) in combination with recombinant double mutant heat labile toxin, LT(R192G/L211A), (dmLT), Intradermal fractional dose inactivated polio vaccine (fIPV), Monovalent oral poliomyelitis vaccine (mOPV), Sabin strain
University of Vermont, World Health Organization
Poliomyelitis
10/23
08/24

Download Options